Creutzfeldt Jakob Disease (Cjd) is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.
Creutzfeldt-Jakob Disease (CJD) is a rare, fatal, neurodegenerative disorder classified as a transmissible spongiform encephalopathy (TSE)1 classified as a transmissible spongiform encephalopathy (TSE) or Prion Disease. The disease is caused by an abnormal form
of the prion protein that misfolds and accumulates in the brain2 that misfolds and accumulates in the brain, leading to rapid neuronal death,
spongiform (sponge-like) brain changes, and progressive cognitive decline. CJD affects approximately 1 in 1 million people worldwide annually, making it one of the rarest
neurodegenerative diseases.
- Most common form (85-90% of cases)3
- No known cause or risk factors
- Typically occurs in individuals aged 60-65
- Accounts for approximately 1 case per million population per year
- Caused by mutations in the PRNP gene (prion protein gene)
- Accounts for 10-15% of cases
- Autosomal dominant inheritance pattern
- Tends to occur at younger ages (40-50s)
- Several known mutations (P102L, D178N, E200K, V210I)
- Acquired through medical procedures
- Transmission via:
- Corneal or dura mater grafts
- Contaminated human growth hormone
- Neurosurgical instruments
- Blood transfusions (rare cases)
- Long incubation period (months to years)
- Linked to consumption of products from cattle with BSE (mad cow disease)
- First described in 1996 in the UK
- Affects younger individuals (average age 28)
- Different clinical and pathological features than sporadic CJD
- Can be transmitted through blood
The central mechanism in CJD involves the misfolding of the normal cellular prion protein (PrP^C) into an abnormal, pathogenic form (PrP^Sc):
- PrP^C: Normal cellular prion protein, found on neuronal surfaces
- PrP^Sc: Scrapie isoform - disease-causing, protease-resistant prion protein
- The misfolded protein acts as a template, causing more normal proteins to misfold
- This creates a chain reaction of protein aggregation
- Spongiform changes: Vacuolation of brain tissue (sponge-like appearance)
- Neuronal loss: Death of neurons throughout the brain
- Gliosis: Proliferation of astrocytes (reactive gliosis)
- Prion protein deposition: Amyloid plaques in some cases (especially vCJD)
- Cerebral cortex: Especially frontal and parietal lobes
- Cerebellum: Affected in most cases, causing ataxia
- Basal ganglia: Involved in movement control
- Thalamus: Sensory and motor relay
- Brainstem: In advanced cases
Rapidly Progressive Dementia:
- Memory impairment developing over weeks to months
- Cognitive decline is much faster than Alzheimer's Disease
- May progress to severe dementia within months
Motor Symptoms:
- Ataxia (loss of coordination)
- Myoclonus (muscle jerks) - characteristic symptom
- Parkinsonism (rigidity, tremor)
- Paretic symptoms (weakness)
Other Neurological Signs:
- Visual disturbances
- Dysarthria (slurred speech)
- Dysphagia (difficulty swallowing)
- Hyperreflexia or hyporeflexia
- Primitive reflexes
- Psychiatric symptoms prominent early (depression, anxiety, delusions)
- Sensory abnormalities (pain, paresthesia)
- Ataxia develops later
- Disease duration longer (median 14 months vs 4-6 months)
| Stage |
Symptoms |
| Prodromal |
Fatigue, insomnia, depression, weight loss |
| Early |
Memory problems, confusion, personality changes |
| Middle |
Myoclonus, ataxia, visual disturbances |
| Late |
Severe dementia, mutism, coma |
WHO Diagnostic Criteria for CJD:
- Definite: Neuropathological confirmation or positive PrP^Sc test
- Probable: Progressive dementia + typical EEG + at least 2 of: myoclonus, visual/cerebellar symptoms, pyramidal/extrapyramidal signs, akinetic mutism
- Possible: Progressive dementia + duration <2 years + at least 2 of the above clinical features
Electroencephalography (EEG):
- Characteristic periodic sharp wave complexes (PSWC)
- Present in 60-80% of sporadic CJD cases
- Less common in variant CJD
MRI Brain:
- DWI and FLAIR sequences: Hyperintensities in cortical regions and basal ganglia
- "Cortical ribboning" sign
- "Hockey stick" sign in the thalamus (variant CJD)
Cerebrospinal Fluid Analysis:
- 14-3-3 protein: Elevated in most CJD cases (sensitivity ~92%)
- Total tau: Markedly elevated
- S100b protein: Elevated neuronal damage marker
Genetic Testing:
- PRNP gene sequencing for familial CJD
- Codon 129 polymorphism analysis (methionine/vlaline)
- Can confirm genetic forms and guide prognosis
Brain Biopsy:
- Definitive diagnosis
- Immunohistochemistry for prion protein
- Usually performed only when diagnosis is uncertain
No effective treatment exists for CJD:
- Supportive care is the mainstay
- Management of symptoms (myoclonus, agitation)
- Nutritional support
- Prevention of complications (aspiration, infections)
Clinical Trials:
- Pentosan polysulfate: Variable results, not FDA-approved
- Quinacrine: Antimalarial with antiprion activity - trials inconclusive
- Immunotherapy: Antibodies against prion protein (preclinical)
- Gene silencing: siRNA approaches (experimental)
- Multidisciplinary care team
- Physical therapy for mobility
- Speech therapy for communication
- Nutritional support
- Management of infections
- Psychological support for families
- Incidence: 1-2 per million annually worldwide
- Age: Median onset 60-65 years (sporadic), 40-50 (genetic), 28 (variant)
- Sex: Slight male predominance (1.3:1)
- Duration: Median 4-6 months (sCJD), 14 months (vCJD)
- First identified in 1996 in the UK
- Approximately 230 cases worldwide (as of 2020)
- Majority in the UK (~180 cases)
- Linked to BSE (bovine spongiform encephalopathy) consumption
CJD must be distinguished from other rapidly progressive dementias:
- Alzheimer's Disease (slower progression)
- Lewy Body Dementia (fluctuating cognition, visual hallucinations)
- Frontotemporal Dementia (personality changes, language deficits)
- Vascular Dementia (stepwise progression)
- Autoimmune encephalitis (potentially treatable)
- Paraneoplastic syndromes
- Metabolic encephalopathies
The study of Creutzfeldt Jakob Disease (Cjd) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Prusiner SB-disease)
- ##. Prions. Proc Natl Acad Sci U S A. 1998;95(23):13363-13383.
- Collins SJ et al. Molecular biology of prion diseases. Brain Pathol. 2004;14(1):87-96.
- Brown P et al. Iatrogenic Creutzfeldt-Jakob Disease: extending the range of risk. Lancet. 2003;362(9392):1460-1462.
- Wadsworth JD et al. Tissue distribution of protease resistant prion protein in variant CJD using a highly sensitive immuno-assay. Lancet. 2001;358(9295):171-180.
- Zerr I et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob Disease. Brain. 2009;132(10):2659-2668.
- Hill AF et al. Molecular classification of sporadic Creutzfeldt-Jakob Disease. Brain. 2003;126(Pt 6):1333-1346.
- Masters CL et al. Creutzfeldt-Jakob Disease: patterns of worldwide occurrence and the significance of familial and sporadic clustering. Ann Neurol. 1979;5(2):177-188.
- Geschwind MD. Rapidly progressive dementia. Continuum (Minneap Minn). 2016;22(2):510-537.
- Budka H et al. Neuropathology of prion diseases. Br Med Bull. 2003;66:121-130.
- Aguzzi A et al. Prion diseases: molecular and cellular basis. Neurobiol Dis. 2020;137:104739.